Smoking Cessation Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

By Company 1.2.2. Analysis by Phase 1.2.3. By Molecule Type 1.2.4. By region 2. Disease Overview 2.1.1. Introduction 2.1.2. Classification 2.1.3. Symptoms 2.1.4. Causes 2.1.5. Diagnoses 2.1.6. Treatment 2.1.7. Epidemiology 3. Executive Summary 4. Market Dynamics 4.1. Drivers 4.2. Restraints 4.3. Opportunities 5. Pipeline Analysis/Outlook 5.1. Analysis by Company 5.2. Analysis by Phase 5.2.1. Phase of Development 5.2.1.1. Introduction 5.2.1.1.1. Drug Profile • Drug Name • Generic Name • Synonyms • Company • Collaborator • Route of administration • Target • Mechanism of Action • Technology • Molecule type • CAS Number • Weight • Chemical Formula • IUPAC name • ATC code 5.2.1.1.2. Strategic Developments 5.2.1.1.3. Clinical trials 5.2.1.1.4. Clinical trial results 5.2.1.1.5. Patents 5.2.1.1.6. Technology 5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph) 5.3. By Molecule type 5.4. Analysis by Region 6. Company profiling 6.1. Aradigm Corporation 6.1.1. Introduction 6.1.2. Financials 6.1.3. Products and Services 6.1.4. SWOT 6.2. 22nd Century Limited, LLC 6.2.1. Introduction 6.2.2. Financials 6.2.3. Products and Services 6.2.4. SWOT 6.3. Chrono Therapeutics, Inc. 6.3.1. Introduction 6.3.2. Financials 6.3.3. Products and Services 6.3.4. SWOT 6.4. Invion, Inc. 6.4.1. Introduction 6.4.2. Financials 6.4.3. Products and Services 6.4.4. SWOT 6.5. Selecta Biosciences, Inc 6.5.1. Introduction 6.5.2. Financials 6.5.3. Products and Services 6.5.4. SWOT 6.6. Achieve Life Sciences, Inc 6.6.1. Introduction 6.6.2. Financials 6.6.3. Products and Services 6.6.4. SWOT 6.7. Embera NeuroTherapeutics, Inc. 6.7.1. Introduction 6.7.2. Financials 6.7.3. Products and Services 6.7.4. SWOT 6.8. Lavipharm 6.8.1. Introduction 6.8.2. Financials 6.8.3. Products and Services 6.8.4. SWOT 6.9. Lotus Pharma 6.9.1. Introduction 6.9.2. Financials 6.9.3. Products and Services 6.9.4. SWOT 6.10. Ethismos Research Inc. 6.10.1. Introduction 6.10.2. Financials